Rodman & Renshaw Annual Global Investment Conference
September 10th - 12th, 2017
Lotte New York Palace Hotel, New York City
Rodman & Renshaw will host more than 300 public and private companies at the three-day 19th Annual Global Investment Conference in New York City. This year's conference will connect growth companies together with a vast audience of financial and strategic investors. The more than 2,000 attendees will enjoy access to corporate presentations from growth companies in the healthcare, natural resources, technology, media and telecommunications, cleantech and other industries; investor one-on-one meetings; keynote speakers; and daily networking opportunities over breakfast, lunch and cocktails. For more information on Rodman & Renshaw, visit www.rodmanandrenshaw.com
22nd Century Group (XXII)
22nd Century Group (NYSE: XXII) is a plant biotechnology company focused on genetic engineering and plant breeding which allows the increase or decrease of the level of nicotine in tobacco plants and the level of cannabinoids in cannabis plants. The company's primary mission in tobacco is to reduce the harm caused by smoking. The company's primary mission in cannabis is to develop proprietary hemp/cannabis strains for important new medicines and agricultural crops. For more information, visit the company's website at www.abeonatherapeutics.com.
Acasti Pharma (ACST)
Acasti Pharma (NASDAQ: ACST) is a biopharmaceutical innovator advancing a potentially best-in-class cardiovascular drug, CaPre (omega-3 phospholipid) for the treatment of hypertriglyceridemia, a chronic condition affecting an estimated one-third of the U.S. population. The corporation's strategy is to initially develop and commercialize CaPre for the three to four million patients in the U.S. with severe hypertriglyceridemia. Since inception, Acasti Pharma has focused on addressing a critical market need for an effective, safe and well-absorbing omega-3 therapeutic that can make a positive impact on the major blood lipids associated with cardiovascular disease risk. For more information, visit the company's website at www.abeonatherapeutics.com.
AcelRx Pharmaceuticals (ACRX)
AcelRx Pharmaceuticals (NASDAQ: ACRX) is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain. Its two late-stage product candidates, ARX-04 and Zalviso®, were developed using the company's non-invasive, sublingual formulation technology to deliver sufentanil, an opioid. The product candidates have completed clinical trials and have demonstrated potential for relief of moderate-to-severe acute pain in post-operative and other medically supervised settings. In the United States, AcelRx is planning to develop and commercialize these product candidates, either through its own efforts or in conjunction with partners. Outside of the United States, AcelRx anticipates commercializing these products on a worldwide basis through select regional partnerships. For more information, visit the company's website at www.acelrx.com.
Actinium Pharmaceuticals (ATNM)
Actinium Pharmaceuticals (NYSE: ATNM) is a biopharmaceutical company developing innovative targeted therapies for patients with cancers lacking effective treatment options. Actinium's proprietary platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. The company's lead product candidate Iomab-B is designed to be used, upon approval, in preparing patients for a hematopoietic stem cell transplant. Actinium is also utilizing its alpha-particle technology platform to generate new drug candidates based on antibodies linked to the element Actinium-225 that are directed at various cancers that are blood-borne or form solid tumors. For more information, visit the company's website at www.actiniumpharma.com.
Adaptimmune Therapeutics (ADAP)
Adaptimmune Therapeutics (NASDAQ: ADAP) is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products. The company's unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. Adaptimmune has a number of proprietary clinical programs, and is also developing its NY-ESO SPEAR T-cell program under a strategic collaboration and licensing agreement with GlaxoSmithKline. The company is located in Philadelphia, USA, and Oxfordshire, U.K. For more information, visit the company's website at www.adaptimmune.com.
ADMA Biologics (ADMA)
ADMA Biologics (NASDAQ: ADMA) is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the proposed treatment of Primary Immune Deficiency Disease (PIDD) and the prevention and treatment of certain infectious diseases. ADMA's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. The target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. For more information, visit the company's website at www.admabiologics.com.
Aduro BioTech (ADRO)
Aduro BioTech (NASDAQ: ADRO) is an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro's technology platforms, designed to harness the body's natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro's LADD technology platform is based on proprietary attenuated strains of Listeria that have been engineered to express tumor-associated antigens to induce specific and targeted immune responses. This platform is being developed as a treatment for multiple indications, including mesothelioma, gastric, ovarian, lung and prostate cancers. Additionally, a personalized form of LADD, or pLADD, is being developed utilizing tumor neoantigens that are specific to an individual patient's tumor. For more information, visit the company's website at www.aduro.com.
Advanced Emissions Solutions (ADES)
Advanced Emissions Solutions (NASDAQ: ADES) is a leader in clean coal technology and the associated specialty chemicals, serving the coal-fueled power plant industry. The company's proprietary environmental technologies and specialty chemicals enable power plants to enhance existing air pollution control equipment, minimize mercury, acid gases, and other emissions, maximize capacity, and improve operating efficiency to meet the challenges of existing and pending emission control regulations. Advanced Emissions Solutions serves as the holding company for ADA-ES, Inc. and is an owner in Tinuum Group, LLC. For more information, visit the company's website at www.advancedemissionssolutions.com.
Advaxis (NASDAQ: ADXS) is a late-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm Technology. Lm Technology is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T cells directed against cancer antigens and neutralize Tregs and myeloid-derived suppressor cells (MDSCs) that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis' lead Lm Technology™ immunotherapies are in clinical trials for invasive and metastatic cervical cancer, head and neck cancer and anal cancer. For more information, visit the company's website at www.advaxis.com.
Aethlon Medical (AEMD)
Aethlon Medical (NASDAQ: AEMD) creates medical technologies to address unmet needs in global health and biodefense. The Aethlon Hemopurifier® is a clinical-stage therapeutic device that eliminates life-threatening viruses from the circulatory system of infected individuals. The device has been validated to capture Ebola, Zika, Lassa, MERS-CoV, HIV, Hepatitis C, Cytomegalovirus, Epstein-Barr, Herpes Simplex, Chikungunya, Dengue, West Nile, Smallpox related viruses, H1N1 Swine Flu, and H5N1 Bird Flu. Aethlon is also the majority owner of Exosome Sciences, Inc., a company focused on the discovery of exosomal biomarkers to diagnose and monitor life-threatening diseases. For more information, visit the company's website at www.aethlonmedical.com.
Aevi Genomic Medicine (GNMX)
Aevi Genomic Medicine (NASDAQ: GNMX) is dedicated to unlocking the potential of genomic medicine to translate genetic discoveries into novel therapies. Driven by a commitment to patients with pediatric onset life-altering diseases, the company's research and development efforts leverages an internal genomics platform and an ongoing collaboration with the Center for Applied Genomics at The Children's Hospital of Philadelphia. For more information, visit the company's website at www.aevigenomics.com.
Agile Therapeutics (AGRX)
Agile Therapeutics (NASDAQ: AGRX) is a women's healthcare company dedicated to fulfilling the unmet health needs of today's women. The company's product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. The company's lead product candidate, Twirla® is a once-weekly prescription contraceptive patch that recently completed phase 3 trials. Twirla is based on proprietary transdermal patch technology which is designed to provide advantages over currently available patches and is intended to optimize patch adhesion and patient wear ability. For more information, please visit the company's website at www.agiletherapeutics.com.
Airborne Wireless Network (ABWN)
Airborne Wireless Network (OTC: ABWN) is focused on creating a high-speed broadband airborne wireless network by linking commercial aircraft in flight. Each aircraft participating in the network will act as an airborne repeater or router, sending and receiving broadband signals from one aircraft to the next and creating a digital superhighway in the sky. The company intends the network to be a high-speed broadband internet pipeline to improve coverage connectivity. The company does not intend to provide retail customer coverage to end users, but, instead, act as a wholesale carrier with target customers, such as internet service providers and telephone companies. For more information, visit the company's website at www.airbornewirelessnetwork.com.
Akebia Therapeutics (AKBA)
Akebia Therapeutics (NASDAQ: AKBA) is a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor biology. Akebia's lead product candidate, vadadustat, is an oral, investigational therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. Akebia's global phase 3 program for vadadustat, which includes the PRO2TECT studies for non-dialysis patients with anemia secondary to chronic kidney disease and the INNO2VATE studies for dialysis-dependent patients, is currently ongoing. For more information, visit the company's website at www.akebia.com.
Albireo Pharma (ALBO)
Albireo Pharma (NASDAQ: ALBO) is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo's clinical pipeline includes a phase 3 product candidate, a phase 2 product candidate, and a product candidate for which an application for regulatory approval has been submitted in Japan. Albireo was spun out from AstraZeneca in 2008. Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary, Albireo AB, is located in Gothenburg, Sweden. For more information, visit the company's website at www.albireopharma.com.
Alimera Sciences (ALIM)
Alimera Sciences (NASDAQ: ALIM) is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera's commitment to retina specialists and their patients is manifest in Alimera's product and development portfolio designed to treat early- and late-stage diseases. For more information, visit the company's website at www.alimerasciences.com.
Alliqua BioMedical (ALQA)
Alliqua BioMedical (NASDAQ: ALQA) is a regenerative technologies company committed to restoring tissue and rebuilding lives. Alliqua offers solutions that allow clinicians to utilize the latest advances in regenerative technologies to bring improved patient outcomes to their practices. Alliqua currently markets the human biologic regenerative technologies, Biovance® and Interfyl™. The company also markets its UltraMIST® Therapy System, which uses painless, noncontact low-frequency ultrasound to stimulate cells below the wound bed to promote the healing process. Alliqua also markets its own line of dressings for wound care. For more information, visit the company's website at www.alliqua.com.
Alphatec Spine, Inc. (ATEC)
Alphatec Spine, Inc., a wholly owned subsidiary of Alphatec Holdings (NASDAQ: ATEC), is a medical device company that designs, develops, manufactures and markets spinal fusion technology products and solutions for the treatment of spinal disorders associated with disease and degeneration, congenital deformities and trauma. The company's mission is to improve lives by delivering advancements in spinal fusion technologies. The company and its affiliates market products in the U.S. via a direct sales force and independent distributors. For more information, visit the company's website at www.alphatecspine.com.
Altimmune (NASDAQ: ALT) is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease and on the development of two next-generation anthrax vaccines that are intended to improve protection and safety while having favorable dosage and storage requirements compared to other anthrax vaccines. The company has two proprietary platform technologies, RespirVec and Densigen, each of which has been shown to activate the immune system in distinctly different ways than traditional vaccines. For more information, visit the company's website at www.altimmune.com.
Amarin (NASDAQ: AMRN) is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Amarin's clinical program includes a commitment to an ongoing outcomes study. Vascepa®, Amarin's first FDA approved product, is a highly-pure, omega-3 fatty acid product available by prescription. For more information, visit the company's website at www.amarincorp.com.
Americas Silver (USAS)
Americas Silver (NASDAQ: USAS) is a silver mining company focused on growth in precious metals from its existing asset base and execution of targeted accretive acquisitions. It owns and operates the Cosalá Operations in Sinaloa, Mexico and the Galena Complex in Idaho, USA. The Company has acquired an option on the San Felipe development project in Sonora, Mexico. For more information, visit the company's website at www.americassilvercorp.com.
Ampio Pharmaceuticals (AMPE)
Ampio Pharmaceuticals (NYSE MKT: AMPE) is a development stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. The company is developing compounds that decrease inflammation by (i) inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and the transcription level; (ii) activating specific phosphatase or depletion of the available phosphate needed for the inflammation process; and (iii) decreasing vascular permeability. For more information, visit the company's website at www.ampiopharma.com.
AmpliPhi Biosciences (APHB)
AmpliPhi Biosciences (NYSE: APHB) is a biotechnology company pioneering the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. AmpliPhi recently announced an additional near-term strategic emphasis on developing precisely targeted and personalized bacteriophage therapies for patients with serious or life-threatening antibiotic-resistant infections. AmpliPhi has reported results from two phase 1 clinical trials of AB-SA01, one for the treatment of Staphylococcus aureus in CRS patients (safety and preliminary efficacy) and one to evaluate the safety of AB-SA01 when administered topically to the intact skin of healthy adults. For more information, visit the company's website at www.ampliphibio.com.
Amyris (NASDAQ: AMRS) is an integrated renewable products company that is enabling the world's leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products. The company is delivering it's No Compromise® products across a number of markets, including specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals. For more information, visit the company's website at www.amyris.com.
Antares Pharma (ATRS)
Antares Pharma (NASDAQ: ATRS) focuses on self-administered parenteral pharmaceutical products. The company's product, OTREXUP® injection for subcutaneous use, is approved in the U.S. for the treatment of adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis and adults with severe recalcitrant psoriasis. The company's product Sumatriptan Injection USP, is approved in the U.S. for the acute treatment of migraine and cluster headache and is distributed by Teva Pharmaceutical Industries, Ltd. Antares Pharma is also developing XYOSTED™, an investigational product for testosterone replacement therapy and has filed a New Drug Application with the FDA. For more information, visit the company's website at www.antarespharma.com.
Anthera Pharmaceuticals (ANTH)
Anthera Pharmaceuticals (NASDAQ: ANTH) is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company has two product candidates in development. Sollpura is Anthera's novel biotechnology-derived pancreatic enzyme replacement therapy for the potential treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis. Blisibimod is Anthera's BAFF inhibitor for the potential treatment of IgA nephropathy. For more information, visit the company's website at www.anthera.com.
Applied Genetic Technologies (AGTC)
Applied Genetic Technologies (NASDAQ: AGTC) is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases. AGTC's lead product candidates are designed to treat inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments. AGTC has a significant intellectual property portfolio and extensive expertise in the design of gene therapy products including capsids, promoters and expression cassettes, as well as, expertise in the formulation, manufacture and physical delivery of gene therapy products. For more information, visit the company's website at www.agtc.com.
Apricus Biosciences (APRI)
Apricus Biosciences (NASDAQ: APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus has two product candidates currently in development. Vitaros is a product candidate in the United States for the treatment of erectile dysfunction. RayVa is the company's product candidate in phase 2 development for the treatment of the circulatory disorder Raynaud's phenomenon, secondary to scleroderma, for which Apricus owns worldwide rights. For more information, visit the company's website at www.apricusbio.com.
Aptose Biosciences (APTO)
Aptose Biosciences (NASDAQ: APTO) is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology. Aptose is advancing new therapeutics focused on novel cellular targets on the leading edge of cancer. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. For more information, visit the company's website at www.aptose.com.
Arcadia Biosciences (RKDA)
Arcadia Biosciences (NASDAQ: RKDA) develops agricultural products that create added value for farmers while benefitting the environment and enhancing human health. Arcadia's agronomic performance traits, including nitrogen use efficiency, water use efficiency, salinity tolerance, heat tolerance and herbicide tolerance, are all aimed at making agricultural production more economically efficient and environmentally sound. Arcadia's nutrition traits and products are aimed at creating healthier ingredients and whole foods with lower production costs. For more information, visit the company's website at www.arcadiabio.com.
Arch Therapeutics (ARTH)
Arch Therapeutics (OTC: ARTH) is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma and interventional care. Arch is developing products based on an innovative self-assembling barrier technology platform with the goal of making care faster and safer for patients. Arch's development stage product candidates include the AC5™ Topical Gel and the AC5™ Surgical Hemostatic Device. For more information, visit the company's website at www.archtherapeutics.com.
Artemis Therapeutics (ATMS)
Artemis Therapeutics (OTC: ATMS) is a clinical-stage biopharmaceutical company focused on the development of agents for the prevention and treatment of severe and potentially life-threatening infectious diseases. The company's lead product candidate, artemisone, is a synthetic artemisinin derivative with anti-viral and anti-parasitic properties. The company is currently evaluating artemisone for the treatment of p. falciparum malaria and human cytomegalovirus (HCMV) infection, Artemis is also developing artemisone for the treatment of other virus and parasitic-related clinical indications. For more information, visit the company's website at www.artemis-therapeutics.com.
Asterias Biotherapeutics (AST)
Asterias Biotherapeutics (NYSE: AST) is a biotechnology company pioneering the field of regenerative medicine. The company's proprietary cell therapy programs are based on its pluripotent stem cell and immunotherapy platform technologies. Asterias is presently focused on advancing three clinical-stage programs which have the potential to address areas of very high unmet medical need in the fields of neurology and oncology. For more information, visit the company's website at www.asteriasbiotherapeutics.com.
Aurinia Pharmaceuticals (AUPH)
Aurinia Pharmaceuticals (NASDAQ: AUPH) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need. The company is currently developing voclosporin, an investigational drug, for the treatment of LN. The company is headquartered in Victoria, BC, and focuses its development efforts globally. For more information, visit the company's website at www.auriniapharma.com.
AVEO Pharmaceuticals (AVEO)
AVEO Pharmaceuticals (NASDAQ: AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. The company is focused on developing and commercializing its lead candidate tivozanib, a potent, selective, long half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, in North America as a treatment for renal cell carcinoma. AVEO is leveraging multiple partnerships aimed at developing and commercializing tivozanib in oncology indications outside of North America, and progressing its pipeline of novel therapeutic candidates in cancer, cachexia and Pulmonary Arterial Hypertension. For more information, visit the company's website at www.aveooncology.com.
Avino (NYSE: ASM) is a silver and gold producer with a diversified pipeline of gold, silver and base metals properties in Mexico and Canada employing approximately 500 people. Avino produces from its wholly owned Avino and San Gonzalo Mines near Durango, Mexico, and is currently planning for future production at the Bralorne Gold Mine in British Columbia, Canada. The company's strategy is to create shareholder value through organic growth at the historic Avino Property near Durango, Mexico, and the strategic acquisition of mineral exploration and mining properties. For more information, visit the company's website at www.avino.com.
Aviragen Therapeutics (AVIR)
Aviragen Therapeutics (NASDAQ: AVIR) is focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The company has three Phase 2 clinical stage compounds: vapendavir, a capsid inhibitor for the prevention or treatment of rhinovirus (RV) upper respiratory infections; enzaplatovir (BTA585), a fusion protein inhibitor in development for the treatment of respiratory syncytial virus infections; and BTA074, an antiviral treatment for condyloma caused by human papillomavirus types 6 & 11. The company also receives royalties from marketed influenza products, Relenza® and Inavir®. For more information, visit the company's website at www.aviragentherapeutics.com.
AXIM Biotechnologies (AXIM)
AXIM Biotechnologies (OTC: AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. The company's flagship products include CanChew®, a CBD-based controlled release chewing gum, CanChew+ containing 50 mg of CBD undergoing clinical trials in patients with IBS and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. For more information, visit the company's website at www.aximbiotech.com.
Aytu BioScience (AYTU)
Aytu BioScience (OTC: AYTU) is a commercial-stage specialty life sciences company focused on global commercialization of novel products in the field of urology, with a focus on products addressing vitality, sexual wellness, and reproductive health. The company currently markets two prescription products in the U.S.: Natesto®, the first and only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or "Low T") and ProstaScint® (capromab pendetide), the only FDA-approved imaging agent specific to prostate specific membrane antigen (PSMA) for prostate cancer detection and staging. For more information, visit the company's website at www.aytubio.com.
AzurRx BioPharma (AZRX)
AzurRx BioPharma (NASDAQ: AZRX) is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. MS1819 recombinant lipase for exocrine pancreatic insufficiency is the Company's lead development program, and additional early stage research is being conducted for the prevention of hospital-acquired infections. The company is headquartered in Brooklyn, NY, with scientific operations based in Langlade, France. For more information, visit the company's website at www.azurrx.com.
Ballard Power Systems (BLDP)
Ballard Power Systems (NASDAQ: BLDP) is engaged in the design, development, manufacture, sale and service of proton exchange membrane (PEM) fuel cell products for a range of applications, focusing on the power product markets of heavy-duty motive (consisting of bus and tram applications), portable power, material handling and backup power, as well as the delivery of technology solutions, including engineering services, technology transfer and the license and sale of its intellectual property portfolio and fundamental knowledge for a range of fuel cell applications. For more information, visit the company's website at www.ballard.com.
Bellerophon Therapeutics (BLPH)
Bellerophon Therapeutics (NASDAQ: BLPH) is a clinical-stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The company is developing three product candidates under its INOpulse program, a proprietary pulsatile nitric oxide delivery system: one is for the treatment of pulmonary arterial hypertension; the second is for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease; and the third candidate is for the treatment of pulmonary hypertension associated with Interstitial Lung Disease. For more information, visit the company's website at www.bellerophon.com.
Benitec Biopharma (BNTC)
Benitec Biopharma (NASDAQ: BNTC) is a biotechnology company developing innovative therapeutics based on its patented gene-silencing technology called ddRNAi or 'expressed RNAi.' Based in Sydney, Australia with laboratories in California and licensees around the world, the company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including OPMD, head & neck squamous cell carcinoma, retinal based diseases such as wet age-related macular degeneration, and hepatitis B. Benitec has also licensed ddRNAi to other biopharmaceutical companies for applications including HIV/AIDS, Huntington's Disease, chronic neuropathic pain, cancer immunotherapy and retinitis pigmentosa. For more information, visit the company's website at www.benitec.com.
BeyondSpring (NASDAQ: BYSI) is a global, clinical-stage biopharmaceutical company developing innovative immuno-oncology cancer therapies with a robust pipeline from internal development and from collaboration with Fred Hutchinson Cancer Research Center and University of Washington. BeyondSpring's lead asset, Plinabulin, is in a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and Phase 2/3 clinical trials in the prevention of chemotherapy-induced neutropenia. BeyondSpring has a seasoned management team with many years of experience bringing drugs to market. For more information, visit the company's website at www.beyondspringpharma.com.
Bio-Path (NASDAQ: BPTH) is a biotechnology company focused on developing therapeutic products utilizing DNAbilize™, its proprietary liposomal delivery and antisense technology, to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. Bio-Path's lead product candidate, prexigebersen (BP1001, liposomal Grb2 antisense), is in a phase 2 study for blood cancers and in preclinical studies for solid tumors. Bio-Path's second drug candidate, also a liposomal antisense drug, is ready for the clinic where it will be evaluated in lymphoma and solid tumors. For more information, visit the company's website at www.biopathholdings.com.
BioAmber (NYSE: BIOA) is a renewable materials company. Its innovative technology platform combines biotechnology and catalysis to convert renewable feedstock into building block materials that are used in a wide variety of everyday products including plastics, paints, textiles, food additives and personal care products. For more information, visit the company's website at www.bio-amber.com.
BioDelivery Sciences International (BDSI)
BioDelivery Sciences International (NASDAQ: BDSI) is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine. BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. BDSI's marketed products and those in development address serious and debilitating conditions such as breakthrough cancer pain, chronic pain, and opioid dependence. For more information, visit the company's website at www.bdsi.com.
BioLargo (OTC: BLGO) delivers sustainable technology-based products that help solve some of the most widespread problems threatening the world's supply of water, food, agriculture, healthcare and energy. Its Advanced Oxidation Systems, including its AOS Filter, a developmental product designed to eliminate toxic contaminants in water in a fraction of the time and cost of current technologies. BioLargo also owns a 50% interest in the Isan System, which was honored with a "Top 50 Water Company for the 21st Century" award by the Artemis Project. For more information, visit the company's website at www.biolargo.com.
BioLineRx (NASDAQ: BLRX) is a clinical-stage biopharmaceutical company focused on oncology and immunology. The company in-licenses novel compounds, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization. BioLineRx has a strategic collaboration with Novartis for the co-development of selected Israeli-sourced novel drug candidates; a collaboration agreement with Merck, on the basis of which the company has initiated a phase 2a study in pancreatic cancer using the combination of BL-8040 and Merck's KEYTRUDA®; and a collaboration agreement with Genentech. For more information, visit the company's website www.biolinerx.com.
Bionomics (OTC: BNOEF) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates focused on the treatment of serious central nervous system disorders and on the treatment of cancer. Bionomics' lead drug candidate BNC210, currently in phase 2 for the treatment of generalized anxiety disorder and for post-traumatic stress disorder, is a novel, proprietary negative allosteric modulator of the alpha-7 (α7) nicotinic acetylcholine receptor. For more information, visit the company's website at www.bionomics.com.au.
BioPharmX (NYSE: BPMX) is a Silicon Valley-based specialty pharmaceutical company, which seeks to provide products through proprietary platform technologies for prescription, over-the-counter (OTC), and supplement applications in the health and wellness markets, including dermatology and women's health. For more information, visit the company's website at www.biopharmx.com.
BioSpecifics Technologies (BSTC)
BioSpecifics Technologies (NASDAQ: BSTC) is a biopharmaceutical company that has developed injectable collagenase for thirteen clinical indications to date. Injectable collagenase is marketed as XIAFLEX® in the U.S. for the treatment of Dupuytren's contracture and Peyronie's disease by BioSpecifics' partner, Endo International plc. Endo is partnered with Sobi, Actelion and Asahi Kasei for Dupuytren's contracture and Peyronie's disease outside the U.S. The XIAFLEX research and development pipeline includes several additional promising indications. BioSpecifics is managing the development of XIAFLEX for uterine fibroids and is conducting a Phase 1 clinical trial. For more information, please visit the company's website at www.biospecifics.com.
Biostage (NASDAQ: BSTG) is a biotechnology company developing bioengineered organ implants based on the company's new Cellframe™ technology, which combines a proprietary biocompatible scaffold with a patient's own stem cells to create Cellspan organ implants. Cellspan implants are being developed to treat life-threatening conditions of the esophagus, bronchus or trachea with the hope of dramatically improving the treatment paradigm for patients. Based on its preclinical data, Biostage has selected life-threatening conditions of the esophagus as the initial clinical application of its technology. For more information, visit the company's website at www.biostage.com.
BioTime (NYSE: BTX) is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. Its clinical programs are based on two platform technologies: pluripotent cells and cell/drug delivery. The foundation of BioTime's core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. The foundation of the company's cell delivery platform is its HyStem® cell and drug delivery matrix technology. BioTime also has significant equity holdings in two publicly traded companies, Asterias Biotherapeutics, Inc. and OncoCyte Corporation. For more information, visit the company's website at www.biotimeinc.com.
Breaking Data (BKDCF)
Breaking Data (OTC: BKDCF) is a technology provider of a range of Artificial Intelligence services including; semantic search, machine learning and natural language processing ("NLP"). The company's technology platform has many practical applications, in multiple business and consumer verticals that are immersed in massive media and data rich settings. The company's showcase app, BreakingSports, utilizes semantic machine learning and NLP to track social media in a fully automated, real-time manner for significant sports information and events and distributes summarized information through real-time push notifications to consumers. For more information, visit the company's website at www.breakingdatacorp.com.
Broadway Gold Mining (BDWYF)
Broadway Gold Mining (OTC: BDWYF) is a resource company focused on development-stage projects with advanced exploration potential. The company owns a 100% interest in the Madison copper-gold project located in the Butte-Anaconda mining region of Montana, USA. The Madison project is permitted for exploration and contains a past-producing underground mine that Broadway has refurbished. The company's exploration program has identified new anomalies across its extensive land package that provide compelling drill targets that are believed to be associated with large-scale porphyry mineralization. For more information, visit the company's website at www.broadwaymining.com.
Caladrius Biosciences (CLBS)
Caladrius Biosciences (NASDAQ: CLBS) is a clinical stage development company with cell therapy products in development based on multiple technology platforms and targeting autoimmune and select cardiovascular indications. The company is investigating its lead product candidate, CLBS03, an ex vivo expanded polyclonal T regulatory cell therapy for the treatment of recent-onset type 1 diabetes, in a currently enrolling Phase 2 trial. For more information, visit the company's website at www.caladrius.com.
Can-Fite BioPharma (CANF)
Can-Fite BioPharma (NYSE: CANF) is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, inflammatory disease and sexual dysfunction. The company's lead drug candidate, Piclidenoson, is scheduled to enter a phase 3 trial for rheumatoid arthritis in 2017 and a phase 3 trial for psoriasis in early 2018. Can-Fite's liver cancer drug Namodenoson is in phase 2 trials for patients with liver cancer and is slated to enter phase 2 for the treatment of non-alcoholic steatohepatitis (NASH). For more information, visit the company's website at www.can-fite.com.
Cancer Genetics (CGIX)
Cancer Genetics (NASDAQ: CGIX) is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China and has established strong clinical research collaborations with nationally recognized cancer centers. The company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states. For more information, visit the company's website at www.cancergenetics.com.
Capstone Turbine (CPST)
Capstone Turbine (NASDAQ: CPST) is the world's leading producer of low-emission microturbine systems and was the first to market commercially viable microturbine energy products. Capstone has shipped over 9,000 Capstone Microturbine systems to customers worldwide. These award-winning systems have logged millions of documented runtime operating hours. Capstone is a member of the U.S. Environmental Protection Agency's Combined Heat and Power Partnership, which is committed to improving the efficiency of the nation's energy infrastructure and reducing emissions of pollutants and greenhouse gases. For more information, visit the company's website at www.capstoneturbine.com.
Cardiome Pharma (CRME)
Cardiome Pharma (NASDAQ: CRME) is a specialty pharmaceutical company dedicated to the development and commercialization of innovative therapies that will improve the quality of life and health of patients suffering from disease. Cardiome has two marketed, in-hospital, cardiology products, BRINAVESS®, approved in Europe, Canada, and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults, and AGGRASTAT® a reversible GP IIB/IIIa inhibitor indicated for use in patients with acute coronary syndrome. For more information, visit the company's website at www.cardiome.com.
CareDx (NASDAQ: CDNA), headquartered in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant recipients. CareDx offers products across the transplant testing continuum, including AlloMap® and AlloSure™ for post-transplant surveillance and Olerup SSP®, Olerup QTYPE®, and Olerup SBT™ for pre-transplant HLA testing. For more information, visit the company's website at www.CareDx.com.
CASI Pharmaceuticals (CASI)
CASI Pharmaceuticals (NASDAQ: CASI) is a U.S. based, late-stage biopharmaceutical company focused on the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a focus on commercialization in China. CASI's product pipeline features its lead proprietary drug candidate, ENMD-2076, in multiple phase 2 clinical trials; MARQIBO®; ZEVALIN®; and EVOMELA® - all U.S. Food and Drug Administration approved drugs in-licensed from Spectrum Pharmaceuticals, Inc. for China regional rights, and, proprietary early-stage candidates in preclinical development. For more information, visit the company's website at www.casipharmaceuticals.com.
Catalyst Biosciences (CBIO)
Catalyst Biosciences (NASDAQ: CBIO) is a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications. Catalyst is focused on the field of hemostasis, including the subcutaneous prophylaxis of hemophilia and facilitating surgery in individuals with hemophilia. For more information, visit the company's website at www.catalystbiosciences.com.
Catalyst Pharmaceuticals (CPRX)
Catalyst Pharmaceuticals (NASDAQ: CPRX) is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis and infantile spasms. Firdapse® has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the treatment of LEMS and Orphan Drug designation for LEMS, CMS and myasthenia gravis. Firdapse is the first and only approved drug in Europe for symptomatic treatment in adults with LEMS. For more information, visit the company's website at www.catalystpharma.com.
Cellect Biotechnology (APOP)
Cellect Biotechnology (NASDAQ: APOP) has developed a breakthrough technology for the isolation of stem cells from any given tissue that aims to improve a variety of stem cell applications. The company's technology is expected to provide pharma companies, medical research centers and hospitals with the tools to rapidly isolate stem cells for in quantity and quality that will allow stems cell related treatments and procedures. Cellect's technology is applicable to a wide variety of stem cell related treatments in regenerative medicine and that current clinical trials are aimed at the cancer treatment of bone marrow transplantations. For more information, visit the company's website at www.cellect.co.
Cellectar Biosciences (CLRB)
Cellectar Biosciences (NASDAQ: CLRB) is developing phospholipid drug conjugates (PDCs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. Cellectar's PDC platform is based on the company's proprietary phospholipid ether analogs. These novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers. Cellectar's PDC pipeline includes product candidates for cancer therapy and cancer diagnostic imaging. The company is also developing proprietary PDCs for targeted delivery of chemotherapeutics and has several preclinical stage product candidates. For more information, visit the company's website at www.cellectar.com.
Cesca Therapeutics (KOOL)
Cesca Therapeutics (NASDAQ: KOOL) is a leading regenerative medicine company that develops, commercializes and markets a range of automated technologies for cell-based therapeutics. Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. Cesca is also leveraging its proprietary AutoXpress® technology platform to develop autologous stem cell-based therapies that address significant unmet needs in the vascular, cardiology and orthopedic markets. For more information, visit the company's website at www.cescatherapeutics.com.
Check-Cap (NASDAQ: CHEK) is a clinical-stage medical diagnostics company developing C-Scan®, the first capsule-based system for preparation-free colorectal cancer screening. Utilizing innovative ultra-low dose X-ray and wireless communication technologies, the capsule generates information on the contours of the inside of the colon as it passes naturally. This information is used to create a 3D map of the colon, which allows physicians to look for polyps and other abnormalities. The C-Scan® system is currently not cleared for marketing in any jurisdiction. For more information, visit the company's website at www.check-cap.com.
Checkpoint Therapeutics (CKPT)
Checkpoint Therapeutics (NASDAQ: CKPT), a Fortress Biotech company, is a clinical‐stage, immunooncology biopharmaceutical company focused on the acquisition, development and commercialization of novel, non‐chemotherapy, immune‐enhanced combination treatments for patients with solid tumor cancers. Checkpoint's broad pipeline consists of fully‐human, immuno‐oncology and checkpoint inhibitor antibodies licensed from the Dana‐Farber Cancer Institute that target programmed deathligand1 ("PD‐L1"); glucocorticoid‐induced TNFR‐related protein ("GITR"); and carbonic anhydrase IX ("CAIX"). Checkpoint will also seek to expand its pipeline to create additional proprietary combination therapies that leverage the immune system and complementary mechanisms. For more information, visit the company's website at www.checkpointtx.com.
Chembio Diagnostics (CEMI)
Chembio Diagnostics (NASDAQ: CEMI) develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing $8.0 billion point-of-care testing market. Chembio markets each of its DPP® HIV 1/2 Assay, HIV 1/2 STAT-PAK® Assay, and SURE CHECK® HIV 1/2 Assay, in the U.S. and internationally. Chembio has developed a patented point-of-care test platform technology, the Dual Path Platform (DPP®) technology, which has significant advantages over lateral-flow technologies. This technology is providing Chembio with a significant pipeline of business opportunities for the development and manufacture of new products. For more information, visit the company's website at www.chembio.com.
ChemoCentryx (NASDAQ: CCXI) is a biopharmaceutical company focused exclusively on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. The company's drug candidates target specific chemokines or chemoattractant receptors, thereby blocking the inflammatory response driven by that particular chemokine while leaving the rest of the immune system unaffected. The company goal is to discover, develop and commercialize therapeutics with distinct advantages over currently marketed therapies in areas of research focus, thereby maximizing shareholder value. For more information, visit the company's website at www.chemocentryx.com.
China Information Technology (CNIT)
China Information Technology (NASDAQ: CNIT) is a leading Internet service company that provides integrated cloud-based solutions enabling innovation and smart living in the fields of new media, elevator safety management, education, etc. Through continuous innovation, CNIT is aiming to leverage its proprietary Cloud-Application-Terminal technology to level the competitive landscape in the new media industry and deliver value for its shareholders, employees, customers, and the community. For more information, visit the company's website at www.en.chinacnit.com.
ChromaDex (NASDAQ: CDXC) leverages its complementary business units to discover, acquire, develop and commercialize patented and proprietary ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. In addition to its ingredient technologies unit, the company also has business units focused on natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting. The company's ingredient portfolio is backed with clinical and scientific research, as well as extensive IP protection. For more information, visit the company's website at www.chromadex.com.
Codexis (NASDAQ: CDXS) is a leading protein engineering company that applies its technology to the development of biocatalysts for commercial manufacture of pharmaceuticals and fine chemicals, as well as the development of enzymes as biotherapeutics and for molecular diagnostics. Codexis' proven technology enables implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable manufacturing. For more information, visit the company's website at www.codexis.com.
CohBar (OTC: CWBR) is a biotechnology company focused on the research and development of mitochondria based therapeutics (MBTs), an emerging class of drugs for the treatment of age-related diseases. MBTs originate from the discovery by CohBar's founders of a novel group of peptides within the mitochondrial genome which regulate metabolism and cell death, and whose biological activity declines with age. CohBar's efforts focus on the development of these mitochondrial-derived peptides (MDPs) into clinically relevant MBTs that offer potential to address age-related diseases. To date, CohBar and its founders have discovered more than 65 MDPs. For more information, visit the company's website at www.cohbar.com.
Collegium Pharmaceutical (COLL)
Collegium Pharmaceutical (NASDAQ: COLL) is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its proprietary DETERx® technology platform for the treatment of chronic pain and other diseases. The DETERx technology platform is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options. For more information, visit the company's website at www.collegiumpharma.com.
Conatus Pharmaceuticals (CNAT)
Conatus Pharmaceuticals (NASDAQ: CNAT) is a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease. In collaboration with Novartis, Conatus is developing its lead compound, emricasan, for the treatment of patients with chronic liver disease. Emricasan is a first-in-class, orally active pan-caspase inhibitor designed to reduce the activity of enzymes that mediate inflammation and apoptosis. Conatus believes that by reducing the activity of these enzymes, caspase inhibitors have the potential to interrupt the progression of a variety of diseases. For more information, visit the company's website at www.conatuspharma.com.
ContraVir (NASDAQ: CTRV) is a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies with a specific focus on developing a potentially curative therapy for hepatitis B virus (HBV). The company is developing two novel anti-HBV compounds with complementary mechanisms of action. ContraVir is also developing Valnivudine™, an orally available nucleoside analogue prodrug; Valnivudine™ is currently in phase 3 for the treatment of herpes zoster. For more information, visit the company's website at www.contravir.com.
Corium International (CORI)
Corium International (NASDAQ: CORI) is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage the company's broad experience with advanced transdermal and transmucosal delivery systems. Corium has multiple proprietary programs in preclinical and clinical development, focusing primarily on the treatment of neurological disorders, with lead programs in Alzheimer's disease. Corium has developed and is the sole commercial manufacturer of seven prescription drug and consumer products with partners Mayne Pharma and Procter & Gamble. For more information, visit the company's website at www.coriumgroup.com.
CorMedix (NYSE: CRMD) is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The company continues emphasis on developing its lead product Neutrolin®, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters. Such infections cost the U.S. healthcare system approximately $6 billion annually and contribute significantly to increased morbidity and mortality. Neutrolin is currently in a phase 3 clinical trial in patients undergoing chronic hemodialysis via a central venous catheter. For more information, visit the company's website at www.cormedix.com.
Crexendo (OTC: CXDO) is a full-service cloud solutions provider that delivers critical voice and data technology infrastructure services to the start-up, SMB and small enterprise markets. Crexendo is comprised of industry-leading engineering, sales, marketing and support professionals that combine left-brain logic with right-brain creativity to design, build and deliver world-class cloud services that drive business productivity. For more information, visit the company's website at www.crexendo.com.
Critical Outcome Technologies (COTQF)
Critical Outcome Technologies (OTC: COTQF) is a clinical stage biotech company that uses proprietary artificial intelligence technologies to pursue a targeted and transformational approach to treating cancer and other unmet medical needs. The company's CHEMSAS® technology accelerates the discovery and development of novel drug therapies, allowing it to build a pipeline of potential drug candidates faster and with a higher probability of success than traditional methods. The company's lead compound, COTI-2, has a novel p53-dependent mechanism of action with selective and potent anti-cancer activity. For more information, visit the company's website at www.criticaloutcome.com.
Cyclacel Pharmaceuticals (CYCC)
Cyclacel Pharmaceuticals (NASDAQ: CYCC) is a clinical-stage biopharmaceutical company using cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases. Cyclacel's transcriptional regulation program is evaluating CYC065, a CDK inhibitor, in patients with advanced cancers. Cyclacel is analyzing stratified and exploratory subgroups from a phase 3 study of sapacitabine in elderly patients with AML. Cyclacel's strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a pipeline of novel drug candidates. For more information, visit the company's website at www.cyclacel.com.
CytoDyn (OTC: CYDY) is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of HIV infection. The company has one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which has completed phase 2 clinical trials with demonstrated antiviral activity in man and is currently in phase 3. CytoDyn intends to continue to develop PRO 140 as a therapeutic anti-viral agent in persons infected with HIV and to pursue non-HIV indications where CCR5 and its ligand CCL5 may be involved. For more information, visit the company's website at www.cytodyn.com.
Cytokinetics (NASDAQ: CYTK) is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company is developing small molecule drug candidates specifically engineered to increase muscle function and contractility. Cytokinetics' lead drug candidate is tirasemtiv, a fast skeletal muscle troponin activator. Tirasemtiv is the subject of VITALITY-ALS, an international phase 3 clinical trial in patients with ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the FDA for the potential treatment of ALS. For more information, visit the company's website at www.cytokinetics.com.
Cytosorbents (NASDAQ: CTSO) is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 44 countries around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the "cytokine storm" or "cytokine release syndrome" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury and pancreatitis, as well as in cancer immunotherapy. CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators. For more information, visit the company's website at www.cytosorbents.com.
CytRx (NASDAQ: CYTR) is a biopharmaceutical company specializing in research and clinical development of novel anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of drug at the tumor. Aldoxorubicin, CytRx's most advanced drug conjugate, is an improved version of the widely used chemotherapeutic agent doxorubicin. CytRx is also rapidly expanding its pipeline of ultra-high potency oncology candidates through its LADR™ technology platform, a discovery engine designed to leverage CytRx's expertise in albumin biology and linker technology for the development of a new class of potential breakthrough anti-cancer therapies. For more information, visit the company's website at www.cytrx.com.
DBV Technologies (DBVT)
DBV Technologies (NASDAQ: DBVT) is developing Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV's method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV's food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. For more information, visit the company's website at www.dbv-technologies.com.
DelMar Pharmaceuticals (DMPI)
DelMar Pharmaceuticals (NASDAQ: DMPI) is developing cancer therapies in indications where patients are failing or have become intolerable to modern targeted or biologic treatments. The company's pipeline is based around VAL-083, a "first-in-class," small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers including glioblastoma multiforme, ovarian and other solid tumors in U.S. clinical trials sponsored by the National Cancer Institute. VAL-083 has been granted orphan drug designation by the FDA for the treatment of glioma, medulloblastoma and ovarian cancer, and in Europe for the treatment of malignant glioma. For further information, please visit www.delmarpharma.com.
Dicerna Pharmaceuticals (DRNA)
Dicerna Pharmaceuticals (NASDAQ: DRNA) is a biopharmaceutical company focused on the discovery and development of innovative RNAi-based therapeutics for diseases involving the liver, including rare diseases, chronic liver diseases, cardiovascular diseases, and viral infectious diseases. The company is leveraging its proprietary GalXC™ RNAi technology platform to build a broad pipeline in these core therapeutic areas, focusing on target genes where connections between target gene and diseases are well understood and documented. The company intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners. For more information, visit the company's website at www.dicerna.com.
Diffusion Pharmaceuticals (DFFN)
Diffusion Pharmaceuticals (NASDAQ: DFFN) is a clinical stage biotechnology company focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard of care treatments. Diffusion is developing its lead product candidate, trans sodium crocetinate (TSC), for use in the many cancer types in which tumor hypoxia is known to diminish the effectiveness of current treatments. TSC targets the cancer's hypoxic micro-environment, re-oxygenating treatment-resistant tissue and making the cancer cells more vulnerable to the therapeutic effects of treatments such as radiation therapy and chemotherapy. For more information, visit the company's website at www.diffusionpharma.com.
DRDGOLD (NYSE: DRD) is a mid-tier, unhedged gold producer and a world leader in surface gold tailings retreatment. In FY2016 the company produced 143 457oz and declared mineral resources of 50.67 Moz and mineral reserves of 1.8Moz. DRDGOLD's strategy is to enhance shareholder value in the short and medium term by continuing to produce gold ounces from its 11.7Moz resource while simultaneously ensuring that the business remains sustainable well into the 21st Century. For more information, visit the company's website at www.drdgold.com.
DURECT (NASDAQ: DRRX) is a biopharmaceutical company actively developing new therapeutics based on its Epigenetic Regulator Program and proprietary drug delivery platforms. DUR 928, a new chemical entity in phase 1 development, is the lead candidate in DURECT's Epigenetic Regulator Program. An endogenous, orally bioavailable small molecule, DUR-928 has been shown in preclinical studies to play an important regulatory role in lipid homeostasis, inflammation, and cell survival. DURECT's advanced oral, injectable, and transdermal delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs. For more information, visit the company's website at www.durect.com.
EDAP TMS (EDAP)
EDAP TMS (NASDAQ: EDAP) markets today Ablatherm® for high-intensity focused ultrasound (HIFU) for prostate tissue ablation in the U.S. and for treatment of localized prostate cancer in the rest of the world. HIFU treatment is shown to be a minimally invasive and effective option for prostatic tissue ablation with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. For more information, visit the company's website at www.edap-tms.com.
Eiger BioPharmaceuticals (EIGR)
Eiger BioPharmaceuticals (NASDAQ: EIGR) is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare diseases. The company has built a diverse portfolio of well-characterized product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which an effective therapy is urgently needed. For more information, visit the company's website at www.eigerbio.com.
Eleven Biotherapeutics (EBIO)
Eleven Biotherapeutics (NASDAQ: EBIO) is a late-stage clinical oncology company advancing a broad pipeline of novel product candidates based upon the company's targeted protein therapeutics (TPTs) platform. The company's TPTs incorporate a tumor-targeting antibody fragment and a protein cytotoxic payload into a single protein molecule in order to achieve focused tumor cell killing. The company believes its TPT approach offers significant advantages in treating cancer over existing antibody drug conjugate technologies. The company also believes TPTs provide effective tumor targeting with broader cancer cell-killing properties than are achievable with small molecule payloads. For more information, visit the company's website at www.elevenbio.com.
eMagin (NYSE MKT: EMAN) is a leader in OLED microdisplay technology, OLED microdisplay manufacturing know-how and mobile display systems. eMagin manufactures high-resolution OLED microdisplays and integrates them with magnifying optics to deliver virtual images comparable to large-screen computer and television displays in portable, low-power, lightweight personal displays. eMagin microdisplays provide near-eye imagery in a variety of products from military, industrial, medical and consumer OEMs. For more information, visit the company's website at www.emagin.com.
Endeavour Silver (EXK)
Endeavour Silver (NYSE: EXK) is a mid-tier precious metals mining company that owns three high grade, underground, silver-gold mines in Mexico. Since start-up in 2004, Endeavour has grown its mining operations organically to produce 9.7 million ounces of silver and equivalents in 2016. The company finds, builds and operates quality silver mines in a sustainable way to create real value for all stakeholders. For more information, visit the company's website at www.edrsilver.com.
Energy Fuels (UUUU)
Energy Fuels (NYSE: UUUU) is a leading integrated US-based uranium mining company, supplying U3O8 to major nuclear utilities. Energy Fuels holds three of America's key uranium production centers, the White Mesa Mill in Utah, the Nichols Ranch Processing Facility in Wyoming, and the Alta Mesa Project in Texas. Energy Fuels also has the largest NI 43-101 compliant uranium resource portfolio in the U.S. among producers, and uranium mining projects located in a number of Western United States, and mineral properties in various stages of permitting and development. For more information, visit the company's website at www.energyfuels.com.
ESSA (NASDAQ: EPIX) is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of castrate-resistant prostate cancer (CRPC) in patients whose disease is progressing despite treatment with current therapies. ESSA believes that its product candidate, EPI-506, can significantly expand the interval of time in which patients suffering from CRPC can benefit from hormone-based therapies. For more information, visit the company's website at www.essapharma.com.
Evoke (NASDAQ: EVOK) is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The company is developing Gimoti, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent gastroparesis in women with diabetes mellitus. Diabetic gastroparesis afflicts millions of sufferers worldwide. Metoclopramide is the only product currently approved in the United States to treat gastroparesis, and is currently available only in oral and intravenous forms. Gimoti is a novel formulation of this drug, designed to provide systemic delivery of metoclopramide through nasal administration. For more information, visit the company's website at www.evokepharma.com.
Eyegate (NASDAQ: EYEG) is a clinical-stage specialty pharmaceutical company that is focused on developing and commercializing products for treating diseases and disorders of the eye. EyeGate is developing products using CMHA-S, a modified form of the natural polymer hyaluronic acid, which possesses unique physical and chemical properties such as hydration and healing properties. The ability of CMHA-S to adhere longer to the ocular surface, resist degradation and protect the ocular surface makes it well-suited for treating various ocular surface injuries. For more information, visit the company's website at www.eyegatepharma.com.
Fennec Pharmaceuticals (FENCF)
Fennec Pharmaceuticals (OTC: FENCF) is a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced chemotherapy ototoxicity in pediatric patients. STS has received Orphan Drug Designation in the U.S. in this setting. For more information, visit the company's website at www.fennecpharma.com.
Fibrocell Science (FCSC)
Fibrocell Science (NASDAQ: FCSC) is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs for diseases affecting the skin and connective tissue. Fibrocell's most advanced product candidate, FCX-007, is the subject of a Phase 1/2 clinical trial for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Fibrocell is in pre-clinical development of FCX-013, its product candidate for the treatment of moderate to severe localized scleroderma. Fibrocell's gene therapy portfolio is being developed in collaboration with Intrexon Corporation (NYSE: XON), a leader in synthetic biology. For more information, visit the company's website at www.fibrocell.com.
First Majestic (AG)
First Majestic (NYSE: AG) is a mining company focused on silver production in Mexico and is aggressively pursuing the development of its existing mineral property assets. The company presently owns and operates six producing silver mines; the La Parrilla Silver Mine, the San Martin Silver Mine, the La Encantada Silver Mine, the La Guitarra Silver Mine, Del Toro Silver Mine and the Santa Elena Silver/Gold Mine. Production from these six mines is projected to be between 11.1 to 12.4 million ounces of pure silver or 16.6 to 18.5 million ounces of silver equivalents in 2017. For more information, visit the company's website at www.firstmajestic.com.
Flex Pharma (FLKS)
Flex Pharma (NASDAQ: FLKS) is a clinical-stage biotechnology company that is developing innovative and proprietary treatments for cramps and spasticity associated with the severe neurological diseases of ALS, MS and peripheral neuropathies such as Charcot-Marie-Tooth (CMT). The company's lead candidate, FLX-787, is being developed under Fast Track designation for the treatment of severe muscle cramps associated with ALS. Flex Pharma was founded by National Academy of Science members and recognized leaders in the fields of ion channels and neurobiology. For more information, visit the company's website at www.flex-pharma.com.
Fortress Biotech (FBIO)
Fortress Biotech (NASDAQ: FBIO) is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress develops and commercializes products both within Fortress and through certain subsidiary companies, also known as Fortress Companies. In addition to internal development programs, Fortress leverages its biopharmaceutical business expertise and drug development capabilities and provides funding and management services to help Fortress Companies achieve goals. Fortress and the Fortress Companies may seek licensing arrangements, acquisitions, partnerships, joint ventures and/or public and private financings to accelerate and support research and development programs. For more information, visit the company's website at www.fortressbiotech.com.
FTE Networks (FTNW)
FTE Networks (OTC: FTNW) is a leading network infrastructure solutions provider to the technology and communications sectors. FTE's three complementary businesses are: FTE Networks Services; CrossLayer, Inc.; and Benchmark Builders, Inc., which provide end-to-end design, build and support solutions for state-of-the-art networks and commercial properties to create the most transformative smart platforms and buildings. FTE's businesses are predicated on smart design and consistent standards that reduce deployment costs and accelerate delivery of innovative projects and services. For more information, visit the company's website at www.ftenet.com.
Galapagos (NASDAQ: GLPG) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. The company pipeline comprises phase 3, phase 2, phase 1, pre-clinical, and discovery programs in cystic fibrosis, inflammation, fibrosis, osteoarthritis and other indications. The company has discovered and developed filgotinib: in collaboration with Gilead and aims to bring this JAK1-selective inhibitor for inflammatory indications to patients all over the world. Galapagos is focused on the development and commercialization of novel medicines that will improve people's lives. For more information, visit the company's website at www.glpg.com.
Galectin Therapeutics (GALT)
Galectin Therapeutics (NASDAQ: GALT) is developing promising therapies for the treatment of fibrotic liver disease, skin diseases, and cancer based on the company's unique understanding of galectin proteins, which are key mediators of biologic function. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. The company is pursuing a development pathway to clinical enhancement and commercialization for its lead compounds in liver fibrosis and cancer. For more information, visit the company's website at www.galectintherapeutics.com.
Galmed Pharmaceuticals (GLMD)
Galmed Pharmaceuticals (NASDAQ: GLMD) is a clinical-stage biopharmaceutical company focused on the development of Aramchol™, a first in class, novel, once-daily, oral therapy for the treatment of NASH for variable populations, as well as other liver associated disorders. Galmed is currently conducting the ARREST Study, a multicenter, randomized, double blind, placebo-controlled Phase IIb clinical study designed to evaluate the efficacy and safety of Aramchol™ in subjects with NASH, who are overweight or obese, and who are pre-diabetic or type-II-diabetic. For more information, visit the company's website at www.galmedpharma.com.
General Moly (GMO)
General Moly (NYSE: GMO) is a U.S.-based molybdenum mineral development, exploration and mining company. The company's primary asset, an 80% interest in the Mt. Hope Project located in central Nevada, is considered one of the world's largest and highest grade molybdenum deposits. Combined with the company's wholly owned Liberty Project, a molybdenum and copper property also located in central Nevada, General Moly's goal is to become the largest pure play primary molybdenum producer in the world. For more information, visit the company's website at www.generalmoly.com.
Gevo (NASDAQ: GEVO) is a leading renewable technology, chemical products, and next generation biofuels company. Gevo has developed proprietary technology that uses a combination of synthetic biology, metabolic engineering, chemistry and chemical engineering to focus primarily on the production of isobutanol, as well as related products from renewable feedstocks. Gevo's strategy is to commercialize bio-based alternatives to petroleum-based products to allow for the optimization of fermentation facilities' assets, with the ultimate goal of maximizing cash flows from the operation of those assets. For more information, visit the company's website at www.gevo.com.
Gilat Satellite Networks (GILT)
Gilat Satellite Networks (NASDAQ: GILT) is a leading global provider of satellite-based broadband communications. The company designs and manufactures cutting-edge ground segment equipment, and provide comprehensive solutions and end-to-end services. Gilat's comprehensive solutions support multiple applications with a full portfolio of products to address key applications including broadband access, cellular backhaul, enterprise, in-flight connectivity, maritime, trains, defense and public safety, all while meeting the most stringent service level requirements. For more information, visit the company's website at www.gilat.com.
GoldMining (OTC: GLDLF) is a public mineral exploration company focused on the acquisition and development of gold projects in Colombia and other regions of the Americas. GoldMining is advancing its Titiribi and La Mina Gold-Copper Projects located in the Department of Antioquia, Colombia, its Cachoeira and São Jorge Gold Projects located in the State of Pará, northeastern Brazil, its Whistler Gold-Copper Project located in the State of Alaska, United States of America, and its Rea Uranium Project in the western Athabasca Basin in northeast Alberta, Canada. For more information, visit the company's website at www.goldmining.com.
Great Panther Silver (GPL)
Great Panther Silver (NYSE: GPL) is a primary silver mining and exploration company. Great Panther's current activities are focused on the mining of precious metals from its two wholly-owned operating mines in Mexico: the Guanajuato Mine Complex, which includes the San Ignacio Mine; and the Topia Mine in Durango; and on advancing the development of the Coricancha Mine Complex in Peru. The company's activities also include the pursuit of additional mining opportunities in the Americas. For more information, visit the company's website at www.greatpanther.com.
Heat Biologics (HTBX)
Heat Biologics (NASDAQ: HTBX) is an immuno-oncology company developing therapies designed to activate a patient's immune system against cancer. Heat has generated highly specific T cell-stimulating therapeutic platform technologies, known as ImPACTand ComPACT. These technologies, in combination with other therapies such as checkpoint inhibitors, are designed to address three distinct but synergistic mechanisms-of-action: robust activation of CD8+ "killer" T cells; reversal of tumor-induced immune suppression; and T cell co-stimulation to further enhance a patient's immune response. For more information, visit the company's website at www.heatbio.com.
Hecla Mining (HL)
Hecla Mining (NYSE: HL), founded in 1891, is a leading low-cost U.S. silver producer with operating mines in Alaska, Idaho and Mexico, and is a growing gold producer with an operating mine in Quebec, Canada. The company also has exploration and pre-development properties in seven world-class silver and gold mining districts in the U.S., Canada, and Mexico, and an exploration office and investments in early-stage silver exploration projects in Canada. For more information, visit the company's website at www.hecla-mining.com.
Hemispherx Biopharma (HEB)
Hemispherx Biopharma (NYSE: HEB) is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection® and the experimental therapeutics rintatolimod. Rintatolimod is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system. Hemispherx's platform technology includes components for potential treatment of various severely debilitating and life threatening diseases. For more information, visit the company's website at www.hemispherx.net.
Highpower International (HPJ)
Highpower International (NASDAQ: HPJ) produces high-quality Nickel-Metal Hydride (Ni-MH) and lithium-based rechargeable batteries used in a wide range of applications such as electric buses, bikes, energy storage systems, power tools, medical equipment, digital and electronic devices, personal care products, and lighting. Highpower's target customers are Fortune 500 companies and top 20 companies in each vertical segment. The majority of Highpower International's products are distributed to worldwide markets mainly in the United States, Europe, China and Southeast Asia. For more information, visit the company's website at www.highpowertech.com.
Histogenics (NASDAQ: HSGX) is a regenerative medicine company developing and commercializing novel tissue therapies that may offer more rapid and durable recoveries for patients with pain and loss of function due to musculoskeletal conditions. Histogenics' regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering and bioadhesives to create tissue ex-vivo. Histogenics' first investigational product candidate, NeoCart is designed to treat cartilage defects in the knee. The Company recently completed enrollment of its NeoCart phase 3 clinical trial and expects to report topline data in the third quarter of 2018. For more information, visit the company's website at www.histogenics.com.
HTG Molecular Diagnostics (HTGM)
HTG Molecular Diagnostics (NASDAQ: HTGM) is a provider of instruments, reagents and services for molecular profiling applications. Headquartered in Tucson, Arizona, the mission of HTG Molecular Diagnostics (HTG) is to empower precision medicine at the local level. In 2013 the company commercialized its first instrument platform and a portfolio of RNA assays that leveraged HTG's original proprietary nuclease protection chemistry. Continuous improvement led to the 2014 launch of the company's HTG EdgeSeq product line, which automates sample and targeted library preparation for next-generation sequencing. For more information, visit the company's website at www.htgmolecular.com.
iCo Therapeutics (ICOTF)
iCo Therapeutics (OTC: ICOTF) identifies existing development stage assets for use in underserved ocular and infectious diseases. Such assets may exhibit utility in non-ophthalmic conditions outside the company's core focus areas and if so the company will seek to capture further value via partnerships, such as its partnership with Immune Pharmaceuticals (NASDAQ: IMNP), which is in several phase 2 studies involving iCo-008. For more information, visit the company website at www.icotherapeutics.com.
Identiv (NASDAQ: INVE) is a global provider of physical security and secure identification. Identiv's products, software, systems, and services address the markets for physical and logical access control and a wide range of RFID-enabled applications. Customers in the government, enterprise, consumer, education, healthcare and transportation sectors rely on Identiv's access and identification solutions. Identiv's mission is to secure the connected physical world: from perimeter to desktop access, and from the world of physical things to the Internet of Everything. For more information, visit the company's website at www.identiv.com.
Immunomedics (NASDAQ: IMMU) is a clinical-stage biopharmaceutical company developing monoclonal antibody based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Immunomedics' most advanced product candidate is IMMU-132, an antibody-drug conjugate that has received Breakthrough Therapy Designation from the FDA for the treatment of patients with triple-negative breast cancer who have failed at least two prior therapies for metastatic disease. Immunomedics' primary goal is to bring IMMU-132 to market for the benefit of patients and the creation of shareholder value. For more information, visit the company's website at www.immunomedics.com.
Immuron (NASDAQ: IMRN) is a biopharmaceutical company focused on oral immunotherapy utilizing polyclonal antibody products that target the human gut immune system and gut microbiome. Immuron's technology platform is capable of developing and producing an orally stable therapeutic as a potential 'oral targeted therapy' for various immune mediated and inflammatory disorders and other chronic disorders in which the immune system plays a key role in their pathogenesis. These disorders represent areas of growing and unmet medical need, where oral targeted therapy drugs could offer significant advantages. For more information, visit the company's website at www.immuron.com.
Innovus Pharmaceuticals (INNV)
Innovus Pharmaceuticals (OTC: INNV) is an OTC consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men's and women's health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products (b) commercial partners to primary care physicians and (c) directly to consumers. The company actively pursues opportunities where existing prescription drugs have recently, or are expected to, change from prescription to OTC. For more information, visit the company's website at www.innovuspharma.com.
Inovio Pharmaceuticals (INO)
Inovio Pharmaceuticals (NASDAQ: INO) is the only immunotherapy company that has reported generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, Regeneron, Genentech, University of Pennsylvania, DARPA, GeneOne Life Science, Plumbline Life Sciences, ApolloBio Corporation, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, and the U.S. Military HIV Research Program. For more information, visit the company's website at www.inovio.com.
Inpixon (NASDAQ: INPX) is a leader in Indoor Positioning and Data Analytics. Inpixon sensors are designed to find all accessible cellular, Wi-Fi, and Bluetooth devices anonymously. Paired with a high performance, data analytics platform this technology delivers visibility, security, and business intelligence on any commercial or government premises world-wide. Inpixon's products, infrastructure solutions, and professional services group help customers take advantage of mobile, big data, analytics, and the Internet of Things (IoT) to uncover the untold stories of the indoors. For more information, visit the company's website at www.inpixon.com.
InspireMD (NYSE: NSPR) seeks to utilize its proprietary MicroNet™ technology to make its products the industry standard for embolic protection and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events. InspireMD intends to pursue applications of this MicroNet technology in coronary, carotid (CGuard™), neurovascular, and peripheral artery procedures. For more information, visit the company's website at www.inspiremd.com/en/.
IntelGenx Technologies Corp. (IGXT)
IntelGenx Technologies Corp. (OTC: IGXT) is an oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform. IntelGenx' highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx' state-of-the-art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to its clients. For more information, visit the company's website at www.intelgenx.com.
Interpace Diagnostics Group (IDXG)
Interpace Diagnostics Group (NASDAQ: IDXG) is a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for better patient diagnosis and management. The company currently has three commercialized molecular tests; PancraGen® for the diagnosis and prognosis of pancreatic cancer; ThyGenX, for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay and ThyraMIR®, for the diagnosis of thyroid cancer utilizing a proprietary gene expression assay. For more information, visit the company's website at www.interpacediagnostics.com.
Iovance Biotherapeutics (IOVA)
Iovance Biotherapeutics (NASDAQ: IOVA) is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The company's lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocyte (TIL) technology being investigated for the treatment of patients with metastatic melanoma, recurrent and/or metastatic squamous cell carcinoma of the head and neck and recurrent and metastatic or persistent cervical cancer. For more information, visit the company's website at www.iovance.com.
IsoRay (NYSE: ISR) is a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers. The company that designs and develops state-of-the-art, personalized brachytherapy products that provide a more cost-effective cancer treatment. Isoray employs approximately 40 employees, dedicated to the introduction of a unique isotope for the treatment of both common and also difficult to treat cancers. For more information, visit the company's website at www.isoray.com.
Jaguar Health (JAGX)
Jaguar Health (NASDAQ: JAGX) is a natural-products pharmaceuticals company focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. The company's wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. The company's Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. For more information, visit the company's website at www.jaguar.health.
Kadmon Holdings (KDMN)
Kadmon Holdings (NYSE: KDMN) is a fully integrated biopharmaceutical company focused on developing innovative products for significant unmet medical needs. The company has a diversified product pipeline in oncology, autoimmune and fibrotic diseases and genetic diseases. For more information, visit the company's website at www.kadmon.com.
KEMET (NYSE: KEM) a leading global supplier of passive electronic components applies world class service and quality to deliver industry leading, high performance capacitance solutions to its customers around the world and offers the world's most complete line of surface mount and through hole capacitor technologies across tantalum, ceramic, film, aluminum, electrolytic, and paper dielectrics. For more information, visit the company's website at www.kemet.com.
KemPharm (NASDAQ: KMPH) is a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its LATTM (Ligand Activated Therapy) platform technology. KemPharm utilizes its LATTM platform technology to generate improved prodrug versions of FDA-approved drugs in the high need areas of pain, ADHD and other central nervous system disorders. KemPharm's co-lead clinical development candidates are KP415 and KP484, both based on a prodrug of methylphenidate, but with differing extended-release profiles for the treatment of ADHD, and KP201/IR, an acetaminophen-free formulation of the company's immediate release abuse deterrent hydrocodone product candidate, KP201. For more information, visit the company's website at www.kempharm.com.
Kindred Biosciences (KIN)
Kindred Biosciences (NASDAQ: KIN) is a development-stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The company's strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses. The company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes. For more information, visit the company's website at www.kindredbio.com.
Kite Pharma (KITE)
Kite Pharma (NASDAQ: KITE) is a biopharmaceutical company engaged in the development of innovative cancer immunotherapies with a goal of providing rapid, long-term durable response and eliminating the burden of chronic care. The company is focused on chimeric antigen receptor (CAR) and T cell receptor (TCR) engineered cell therapies designed to empower the immune system's ability to recognize and kill tumors. Kite is based in Santa Monica, CA. For more information, visit the company's website at www.kitepharma.com.
La Jolla Pharmaceutical (LJPC)
La Jolla Pharmaceutical (NASDAQ: LJPC) is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The company has several product candidates in development. LJPC-501 is La Jolla's proprietary formulation of synthetic human angiotensin II for potential treatment of catecholamine resistant hypotension. LJPC-401 is La Jolla's proprietary formulation of synthetic human hepcidin for potential treatment of conditions characterized by iron overload. LJPC-30S is La Jolla's next-generation gentamicin derivative program for the potential treatment of serious bacterial infections as well as rare genetic disorders. For more information on La Jolla, please visit www.ljpc.com.
Ligand (NASDAQ: LGND) is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. The company's business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Ligand partners with other pharmaceutical companies to leverage what it does best (late-stage development, regulatory management and commercialization) to ultimately generate revenue. For more information, visit the company's website at www.ligand.com.
Lipocine (NASDAQ: LPCN) is a specialty pharmaceutical company developing innovative pharmaceutical products for use in men's and women's health using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes three development programs. LPCN 1021 is designed to help restore normal testosterone levels in hypogonadal men. LPCN 1111 originated and is being developed by Lipocine as a next-generation oral testosterone product currently in phase 2 testing. LPCN 1107 is potentially the first oral hydroxyprogesterone caproate product candidate indicated for the prevention of recurrent preterm birth and has been granted orphan drug designation by the FDA. For more information, visit the company's website at www.lipocine.com.
MabVax Therapeutics Holdings (MBVX)
MabVax Therapeutics Holdings (NASDAQ: MBVX) is a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the rapid translation into clinical development of products to address unmet medical needs in the treatment of cancer. The company's antibody MVT-5873, is a fully human IgG1 monoclonal antibody (mAb) that targets sialyl Lewis A (sLea), an epitope on CA19-9, and is currently in Phase 1 clinical trials as a therapeutic agent for patients with pancreatic cancer (PDAC) and other CA19-9 positive tumors. CA19-9 is expressed in over 90% of PDAC and in other diseases including small cell lung and GI cancers. For more information, visit the company's website at www.mabvax.com.
Madrigal Pharmaceuticals (MDGL)
Madrigal Pharmaceuticals (NASDAQ: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need. The company's lead candidate, MGL-3196, is a first-in-class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist that is currently in phase 2 development for NASH and HeFH. For more information, visit the company's website at www.madrigalpharma.com.
MAG Silver (MAG)
MAG Silver (NYSE: MAG) is a Canadian exploration and development company focused on becoming a top-tier primary silver mining company, by exploring and advancing high-grade, district scale, silver-dominant projects in the Americas. The company's principal focus and asset is the Juanicipio Property, being developed in partnership with Fresnillo Plc and is located in the Fresnillo Silver District in Mexico, the world's premier silver mining camp. MAG Silver is developing the underground infrastructure on the property, with operational expertise of Fresnillo plc to support an expected 4,000 tons per day mining operation. For more information, visit the company's website at www.magsilver.com.
Magic Software Enterprises (MGIC)
Magic Software Enterprises (NASDAQ: MGIC) is a global provider of enterprise-grade application development and business process integration software solutions and a vendor of a broad range of software and IT services. The company's software solutions are used by thousands of customers of all sizes to develop, deploy and integrate on-premise, mobile and cloud-based business applications quickly and cost effectively to improve operational efficiency and innovation, allowing customers to dramatically improve their business performance and return on investment. For more information, visit the company website at www.magicsoftware.com.
MagneGas (NASDAQ: MNGA) owns a patented process that converts various renewables and liquid wastes into MagneGas fuels. These fuels can be used as an alternative to natural gas or for metal cutting. The company's testing has shown that its metal cutting fuel 'MagneGas2®' is faster, cleaner and more productive than other alternatives on the market. It is also cost effective and safe to use with little changeover costs. The company currently sells MagneGas2® into the metal working market as a replacement to acetylene. For more information, visit the company website at www.magnegas.com.
MannKind (NASDAQ: MNKD) is a biopharmaceutical company that focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes. The company manufactures and commercializes Afrezza® (insulin human) inhalation powder, its first FDA-approved product. For more information, visit the company website at www.mannkindcorp.com.
Marrone Bio Innovations (MBII)
Marrone Bio Innovations (NASDAQ: MBII) is focused on the discovery, development and promotion of biological products for pest management and plant health. MBI's effective and environmentally responsible pest management solutions help customers operate more sustainably while improving plant health and increasing crop yields. MBI currently has six commercially available products as well as eight product candidates in various stages of the company's rapid development pipeline. Marrone Bio Innovations is dedicated to pioneering smart biopesticide solutions for both farmers and consumers around the globe. For more information, visit the company website at www.marronebio.com.
Mateon Therapeutics (MATN)
Mateon Therapeutics (NASDAQ: MATN) is a biopharmaceutical company seeking to realize the full potential of vascular targeted therapy (VTT) in oncology. VTT includes vascular disrupting agents (VDAs) such as the investigational drugs that Mateon is developing, and anti-angiogenic agents (AAs), a number of which are FDA-approved and widely used in cancer treatment. These two approaches have distinct yet complementary mechanisms of action. The company believes that it can significantly improve cancer therapy by employing these two complementary approaches simultaneously. For more information, visit the company website at www.mateon.com.
MaxPoint (NASDAQ: MXPT) is a marketing technology company that generates hyperlocal intelligence to optimize brand and retail performance. MaxPoint provides a platform for brands to connect the digital world with the physical world through hyperlocal execution, measurement, and consumer insights. The company's proprietary Digital Zip® technology and the MaxPoint Intelligence Platform™ predict the most likely buyers of a specific product at a particular retail location and then execute cross-channel digital marketing programs to reach these buyers. For more information, visit the company website at maxpoint.com.
McEwen Mining (MUX)
McEwen Mining (NYSE: MUX) has the goal to qualify for inclusion in the S&P 500 Index by creating a high growth gold and silver producer focused in the Americas. McEwen Mining's principal assets consist of the San José mine in Santa Cruz, Argentina (49% interest), the El Gallo Gold mine and El Gallo Silver project in Mexico, the Gold Bar project in Nevada, the Timmins projects in Canada and the Los Azules copper project in Argentina. For more information, visit the company website at www.mcewenmining.com.
Medical Transcription Billing (MTBC)
Medical Transcription Billing (NASDAQ: MTBC) is a healthcare information technology company that provides a fully integrated suite of proprietary web-based solutions, together with related business services, to healthcare providers throughout the United States. The company's integrated Software-as-a-Service (or SaaS) platform helps customers increase revenues, streamline workflows and make better business and clinical decisions, while reducing administrative burdens and operating costs. For more information, visit the company website at www.MTBC.com.
Medigus (NASDAQ: MDGS) is a medical device company specializing in developing minimally invasive endosurgical tools and highly innovative imaging solutions. The company developed the MUSE™ system, an FDA cleared and CE marked endoscopic device, to perform Transoral Fundoplication (TF) for the treatment of GERD (gastroesophageal reflux disease). MUSE is gaining adoption in key markets around the world and is available in world-leading healthcare institutions in the U.S., Europe and Israel. For more information, visit the company website at www.medigus.com.
Microbot Medical (MBOT)
Microbot Medical (NASDAQ: MBOT) specializes in transformational micro-robotic medical technologies leveraging the natural and artificial lumens within the human body. Microbot's current platforms, ViRob™ and TipCAT™, are comprised of two highly advanced micro-robotic technologies, from which the company is currently developing its first two product candidates: the Self Cleaning Shunt™, or SCS™, for the treatment of hydrocephalus and Normal Pressure Hydrocephalus, or NPH; and a self-propelling, semi-disposable endoscope that is being developed initially for use in colonoscopy procedures. For more information, visit the company website at www.microbotmedical.com.
MicroVision (NASDAQ: MVIS) is the creator of PicoP® scanning technology, an ultra-miniature laser projection and sensing solution based on the laser beam scanning methodology pioneered by the company. MicroVision's business model and product line offering includes display and sensing engines, licensing its patented technology and selling components to licensees for incorporation into their scanning engines. Extensive research has led MicroVision to become an independently recognized leader in the development of intellectual property. MicroVision's IP portfolio has been recognized by the Patent Board as a top 50 IP portfolio among global industrial companies. For more information, visit the company website at www.microvision.com.
Midatech Pharma (MTP)
Midatech Pharma (NASDAQ: MTP) is an international specialty pharmaceutical company focused on oncology and other therapeutic areas with a U.S. commercial operation marketing four cancer care supportive products, and co-promoting two others. Midatech's strategy is to internally develop oncology products and collaborate with partners in other therapy areas, and to drive growth both organically and through strategic acquisitions. The company's R&D activities are supported by two breakthrough drug delivery technologies: Q-Sphera for sustained release and its proprietary gold nanoparticles. For more information, visit the company website at www.midatechpharma.com.
Milestone Scientific (MLSS)
Milestone Scientific (NYSE: MLSS) is a leading medical research and development company that designs and patents innovative injection technology. Milestone's computer-controlled systems make injections precise, efficient, and virtually painless. For more information, visit the company website at www.milestonescientific.com.
Moleculin Biotech (MBRX)
Moleculin Biotech (NASDAQ: MBRX) is a preclinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on discoveries made at MD Anderson Cancer Center. The company's lead product candidate is Annamycin, an anthracycline being studied for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company also has two preclinical small molecule portfolios, one of which is focused on the modulation of hard-to-target tumor cell signaling mechanisms and the recruitment of the patient's own immune system. The other portfolio targets the metabolism of tumors. For more information, visit the company website at www.moleculin.com.
Motif Bio (MTFB)
Motif Bio (NASDAQ: MTFB) is a clinical-stage biopharmaceutical company, engaged in the research and development of novel antibiotics designed to be effective against serious and life-threatening infections in hospitalized patients caused by multi-drug resistant bacteria, including MRSA. The company's lead product candidate, iclaprim, is being developed for high risk MRSA patient populations. The first proposed indication, and near-term commercial opportunity, is for the treatment of acute bacterial skin and skin structure infections, one of the most common bacterial infections, with 3.6 million patients hospitalized annually in the U.S. For more information, visit the company website at www.motifbio.com.
Myomo (NYSE: MYO) is a commercial stage medical robotics company that offers expanded mobility for those suffering from neurological disorders and upper limb paralysis. Based on patented technology developed at MIT and the company, Myomo develops and markets the MyoPro® product line of lightweight, non-invasive, powered arm braces to restore function in the paralyzed or weakened arms and hands of individuals that have suffered a stroke, spinal cord or nerve injury such as brachial plexus injury, or other neuromuscular disability such as amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS). For more information, visit the company website at www.myomo.com.
Learn How to Become a Client-Partner
We have a full suite of powerful communications tools as well as an expansive network of more than 5,000 key distribution points. Interested in putting it all to work for you? Leveraging a professional team of journalists and writers, NNW can introduce you to a wide audience of investors, consumers, journalists and the general public.
If would like to work with us, visit our Become a Client-Partner page.